Investors
CEO Message
Our company's core business is the development of “aptamer drug discovery”, utilising the “flexible folding power” of single-stranded nucleic acids (particularly RNA).
Our main product, umedaptanib pegol (an anti-FGF2 aptamer), is currently undergoing two clinical trials. Firstly, in the United States, we achieved proof of concept (POC) in a Phase 2 clinical trial for exudative age-related macular degeneration, demonstrating that the investigational drug exhibits the intended efficacy in humans.
Additionally, we are conducting a Phase 2 clinical trial for achondroplasia in Japan and have achieved promising results, including significant height gain in paediatric patients. This programme has been designated an orphan drug by the Ministry of Health, Labour and Welfare. We anticipate various preferential measures in the future development of this drug.
Not only is the fact that our umedaptanib pegol has demonstrated clinical efficacy in these two diseases good news for our company, it is also a significant driving force for the development of aptamer drugs, which have been lagging globally.
Last November, I was invited by the Saudi Arabian government to speak at the Riyadh Global Medical Biotechnology Summit 2024. During the summit, we signed a Memorandum of Understanding (MoU) with the King Abdullah International Medical Research Centre (KAIMRC) regarding the development of RNA aptamer drugs. We look forward to future developments that will benefit both our company and Saudi Arabia.
We would like to express our sincere gratitude to everyone who has supported us thus far. We will continue to work hard to meet the expectations of our shareholders.
Yoshikazu Nakamura,PhD,President and CEO
June,2025
Corporate Philosophy
Regardless of the progress made in science and technology, many medical needs remain unmet for cancer, immune disorders, and other incurable diseases. Our objective is to discover innovative aptamer medicines for difficult to treat and incurable diseases in collaboration with other pharmaceutical companies. We plan to launch aptamer medicines as soon as possible to contribute to the health of people.
Fundamental policies for realizing the corporate philosophy
- As a corporation involved in the research and development of pharmaceutical drugs for human life and health, we conduct research based on cutting-edge science and technology with an emphasis on high ethical standards.
- To maximize corporate value and fulfill our social responsibility, we work to strengthen our commitment to the Structure of Corporate Governance and maintain compliance and the appropriate corporate execution of business.
- As a listed corporation, we observe the Standards of Corporate Action developed by the Tokyo Stock Exchange, enhance the disclosure of corporate information, secure the transparency of corporate management, and ensure accountability. Furthermore, we maintain and develop good relationships with shareholders, customers, the local community and other stakeholders.